Latest News
-
TCS Vs Infosys: Dividend History And Upcoming Rewards, Which IT Giant Is Better? -
LIC New Jeevan Shanti 858 Plan: How To Earn Rs 10,000 Pension Per Month After Retirement? Check Eligibility! -
Kronox Lab Sciences Granted SEBI Approval to Initiate IPO -
Big News For F&O Traders! NSE To Launch Derivatives On Nifty Next 50 From April 24; Key Highlights! -
Aadhaar POI, POA Update: How To Submit Your Updated Identity, Address Proof Documents Online? -
Infosys Q4 Profit Surges 30% to Rs 7,969 Crore, Eyes Future Growth -
China Offloads $22.7 Billion in US Treasury Amid Growing Tensions -
7:1 Bonus, Rs 778.75/Sh Dividend In 20 Yrs: Infosys To Offer Massive Rewards, Up Next Rs 28/Sh Payout Soon -
1:1 Bonus, 16.50/Share Dividend: NBFC To Recommend Dividend, Buy For TP Rs 900: Motilal Oswal -
Infosys Q4 Results: Cons PAT Shoots Up 30% YoY To Rs 7,975 Crore; FY25 Guidance Here
Yes Securities' Top 3 Pharma Picks For 2021 After Sector Made A Comeback In 2020
Amid coronavirus pandemic, the pharma sector after underperforming for most of the year 2019 and then witnessing lows in March 2020 on global market rout, showed remarkable resilience. In fact the essential nature of pharma sector came to the fore and there was seen frantic buying of drugs that are chronic in nature such as Diabetes, cardiac, blood pressure etc. In fact from levels of 8060 on Nifty Pharma as on January 1, 2020, the levels on the sectoral index are at 12432 as at the close of December 15, 2020, marking an increase of 54 percent.
Then on repurposed Covid drugs such as Favipiravir, Remdesivir and HCQS resulted in increased revenues both in domestic as well as export markets. Also the pandemic led to buying of immunity boosting products and there was seen traction in domestic therapeutic from cardiac, diabetes and vitamins.
Pharma companies that witnessed sharp rebound in 2020 from March lows
1. Dr. Reddy's
2. Aurobindo
3. Cipla
4. Lupin
5. Sun Pharma
API companies
API companies such as Laurus Labs and Divis Labs largely favoured by pricing factor gained the most
Healthcare groups
Then on as the non-Covid business spiked to 95% of pre-Covid level that got hit as its largely retail driven, there was seen a catch up rally in stocks such as Dr. Lal Path, Metropolis and Apollo Hospitals.
2021 Outlook for Pharma Sector
Now as the vaccine trials are under final stages by several firms in India and abroad, focus would now shift to vaccine production as well as its distribution. And given that companies that are seen to benefit most as per the views of Mr. Bhavesh Gandhi, Lead Analyst - Institutional Equities, YES SECURITIES are Dr Reddys', Aurobindo, Cadila and Wockardt and Serum Institute of India from the unlisted space.
Pharma Stock Picks By Yes Securities For 2021
As the Covid 19 vaccine related opportunity shall be one time in nature, significant weightage to the factor is not given when picking stocks for 2021:
1. Torrent Pharma on the rationale that it has fast growing brands in the domestic market.
2. Aurobindo and Alembic Pharma have been chosen as they can aptly play the US generics growth especially in injectables and sartans opportunity, respectively.
GoodReturns.in
